Clinical, Demographic, and Radiological Characteristics of Patients Demonstrating Antibodies Against Myelin Oligodendrocyte Glycoprotein
dc.contributor.author | Koç S. | |
dc.contributor.author | Şen S. | |
dc.contributor.author | Terzi Y. | |
dc.contributor.author | Kızılay F. | |
dc.contributor.author | Demir S. | |
dc.contributor.author | Aksoy D.B. | |
dc.contributor.author | Kurtuluş F. | |
dc.contributor.author | Bilge N. | |
dc.contributor.author | Idilman E. | |
dc.contributor.author | Uzunköprü C. | |
dc.contributor.author | Güngör S. | |
dc.contributor.author | Çilingir V. | |
dc.contributor.author | Ethemoğlu Ö. | |
dc.contributor.author | Boz C. | |
dc.contributor.author | Gümüş H. | |
dc.contributor.author | Kılıç A.K. | |
dc.contributor.author | Kısabay A. | |
dc.contributor.author | Bir L.S. | |
dc.contributor.author | Turan Ö.F. | |
dc.contributor.author | Soysal A. | |
dc.contributor.author | Köseoğlu M. | |
dc.contributor.author | Uzuner G.T. | |
dc.contributor.author | Bayındır H. | |
dc.contributor.author | Kabay S.C. | |
dc.contributor.author | Çam M. | |
dc.contributor.author | Yayla V. | |
dc.contributor.author | Tan H. | |
dc.contributor.author | Özcan A. | |
dc.contributor.author | Taşkapıoğlu Ö. | |
dc.contributor.author | Korkmaz M. | |
dc.contributor.author | Tamam Y. | |
dc.contributor.author | İnanç Y. | |
dc.contributor.author | Efendi H. | |
dc.contributor.author | Kotan D. | |
dc.contributor.author | Yetkin M.F. | |
dc.contributor.author | Bilgiç A.B. | |
dc.contributor.author | Saçmacı H. | |
dc.contributor.author | Demirci S. | |
dc.contributor.author | Çelik Y. | |
dc.contributor.author | Poyraz T. | |
dc.contributor.author | Terzi M. | |
dc.date.accessioned | 2025-04-10T11:02:53Z | |
dc.date.available | 2025-04-10T11:02:53Z | |
dc.date.issued | 2024 | |
dc.description.abstract | Background: Optic neuritis, myelitis, and neuromyelitis optica spectrum disorder (NMOSD) have been associated with antibodies against myelin oligodendrocyte glycoprotein-immunoglobulin G (anti-MOG-IgG). Furthermore, patients with radiological and demographic features atypical for multiple sclerosis (MS) with optic neuritis and myelitis also demonstrate antibodies against aquaporin-4 and anti-MOG-IgG. However, data on the diagnosis, treatment, follow-up, and prognosis in patients with anti-MOG-IgG are limited. Aims: To evaluate the clinical, radiological, and demographic characteristics of patients with anti-MOG-IgG. Study Design: Multicenter, retrospective, observational study. Methods: Patients with blood samples demonstrating anti-MOG-IgG that had been evaluated at the Neuroimmunology laboratory at Ondokuz Mayıs University’s Faculty of Medicine were included in the study. Results: Of the 104 patients with anti-MOG-IgG, 56.7% were women and 43.3% were men. Approximately 2.4% of the patients were diagnosed with MS, 15.8% with acute disseminated encephalomyelitis (ADEM), 39.4% with NMOSD, 31.3% with isolated optic neuritis, and 11.1% with isolated myelitis. Approximately 53.1% of patients with spinal involvement at clinical onset demonstrated a clinical course of NMOSD. Thereafter, 8.8% of these patients demonstrated a clinical course similar to MS and ADEM, and 28.1% demonstrated a clinical course of isolated myelitis. The response to acute attack treatment was lower and the disability was higher in patients aged > 40 years than patients aged < 40 years at clinical onset. Oligoclonal band was detected in 15.5% of the patients. Conclusion: For patients with NMOSD and without anti-NMO antibodies, the diagnosis is supported by the presence of anti-MOG-IgG. Furthermore, advanced age at clinical onset, Expanded Disability Status Scale (EDSS) score at clinical onset, spinal cord involvement, and number of attacks may be negative prognostic factors in patients with anti-MOG-IgG. © Author(s). | |
dc.identifier.DOI-ID | 10.4274/balkanmedj.galenos.2024.2024-1-97 | |
dc.identifier.uri | http://hdl.handle.net/20.500.14701/44349 | |
dc.publisher | Galenos Publishing House | |
dc.title | Clinical, Demographic, and Radiological Characteristics of Patients Demonstrating Antibodies Against Myelin Oligodendrocyte Glycoprotein | |
dc.type | Article |